Komori
Ono Pharmaceutical (4528) · RiskFirst stated

Risk of Realizing Acquisition Benefits

First written in FY2024. . Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Risk of underperformance and integration failure in M&A and business restructuringA theme 74 companies write about · 76 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2025: 9 of 29 companies on the "Worse" side.

11 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 74 companies compared. The sentences above are computed from all 74.
Full recordFilings, disclosures and news, newest first
  1. FY2024First statedAnnual report

    「When conducting an acquisition, operating results may be affected by changes in the target company’s management or business environment, changes in the external environment such as policy changes in individual countries, and other factors, and the expected benefits of the acquisition may not be realized.」

    The possibility that acquisition benefits may not be realized was explicitly identified for the first time as an independent major strategic risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Realizing Acquisition Benefits | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori